Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women's health, and organ health. The company aims to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions. Natera's proprietary technology combines novel molecular biology techniques with bioinformatics software, allowing for highly accurate detection down to a single molecule in a tube of blood. Their portfolio includes tests like Panorama for non-invasive prenatal screening, Signatera for molecular residual disease detection in cancer, and Prospera for organ transplant assessment. Natera operates CAP-accredited and CLIA-certified laboratories in California and Texas.